NCT Id | NCT04108013 |
---|---|
Title | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC |
Condition | Lung Cancer Stage II |
StudyType | Interventional |
Organization | Xuanwu Hospital, Beijing |
Sponsor/Collaborators | Xuanwu Hospital, Beijing |
Status | Not yet recruiting |
Gender | All |
AgeGroup | Adult Older Adult |
Location (with distance) | |
Description | This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. |